Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Oct 13;18(10):e1010805.
doi: 10.1371/journal.ppat.1010805. eCollection 2022 Oct.

An introduction to the Marburg virus vaccine consortium, MARVAC

Robert W Cross  1 , Ira M Longini  2 , Stephan Becker  3 , Karin Bok  4 , David Boucher  5 , Miles W Carroll  6 , Janet V Díaz  7 , William E Dowling  8 , Ruxandra Draghia-Akli  9 , James T Duworko  10 , John M Dye  11 , Michael A Egan  12 , Patricia Fast  13 , Amy Finan  14 , Courtney Finch  14 , Thomas R Fleming  15 , Joan Fusco  16 , Thomas W Geisbert  1 , Anthony Griffiths  17 , Stephan Günther  18 , Lisa E Hensley  19 , Anna Honko  17 , Ruth Hunegnaw  20 , Jocelyn Jakubik  14 , Julie Ledgerwood  4 , Kerstin Luhn  21 , Demetrius Matassov  12 , Jeffrey Meshulam  12 , Emily V Nelson  18 , Christopher L Parks  13 , Roxana Rustomjee  14 , David Safronetz  22 , Lauren M Schwartz  7 , Dean Smith  23 , Paul Smock  14 , Ydrissa Sow  24 , Christina F Spiropoulou  25 , Nancy J Sullivan  4 , Kelly L Warfield  26 , Daniel Wolfe  23 , Courtney Woolsey  1 , Roland Zahn  21 , Ana María Henao-Restrepo  7 , César Muñoz-Fontela  18 , Andrea Marzi  27
Affiliations

An introduction to the Marburg virus vaccine consortium, MARVAC

Robert W Cross et al. PLoS Pathog. .

Abstract

The emergence of Marburg virus (MARV) in Guinea and Ghana triggered the assembly of the MARV vaccine "MARVAC" consortium representing leaders in the field of vaccine research and development aiming to facilitate a rapid response to this infectious disease threat. Here, we discuss current progress, challenges, and future directions for MARV vaccines.

PubMed Disclaimer

Conflict of interest statement

T.W.G. holds U.S. patent number 7,635,485 issued to US Government, U.S. patent number 7,838,658 issued to Arbutus Biopharma, U.S. patent number 8,017,130 issued to US Government, U.S. patent number 8,716,464 issued to Arbutus Biopharma, and U.S. patent number 8,796,013 issued to Boston University. N.J.S. has a patent for Chimpanzee Adenoviral vector-based filovirus vaccines (for use in humans) with royalties paid to GlaxoSmithKline Biologicals. K.L.W. is a stockholder of Emergent BioSolutions. R.Z. holds a patent for “Methods and compositions for inducing protective immunity against Marburg virus infection”. All other authors declare no conflict of interest. The conclusions in this report are those of the authors and do not necessarily represent the official position of the U.S. Centers for Disease Control and Prevention.

References

    1. Mahase E. Guinea reports west Africa’s first ever case of Marburg virus disease. BMJ. 2021;374:n1988. Epub 2021/08/12. doi: 10.1136/bmj.n1988 . - DOI - PubMed
    1. Prentice A. Guinea declares end of Marburg virus outbreak 2021. 2021 Sept. 23. Available from: https://www.reuters.com/world/africa/guinea-declares-end-marburg-virus-o....
    1. ISID ProMED. Marburg virus disease–Ghana 2022. 2022 Jul 28. Available from: https://promedmail.org/promed-post/?id=8704707. https://promedmail.org/promed-post/?id=8704676.
    1. Slenczka W. Filovirus Research: How it Began. Curr Top Microbiol Immunol. 2017;411:3–21. Epub 2017/08/03. doi: 10.1007/82_2017_8 . - DOI - PubMed
    1. Weidmann M, Hufert FT, Sall AA. Viral load among patients infected with Marburgvirus in Angola. J Clin Virol. 2007;39(1):65–6. Epub 2007/03/16. doi: 10.1016/j.jcv.2006.12.023 . - DOI - PubMed

Publication types